998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study

Abstract

Mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) cancers (ca) are one of the most immunogenic ca. Anti-PD-1 monotherapy using Pembrolizumab has regulatory approval in advanced MSI-H colorectal ca (CRC) and non-CRCs leading to durable responses in a 1/3 of pts. Combined anti-PD-1/CTLA-4 blockade using nivolumab (nivo) and ipilimumab (ipi) has shown superiority to anti-PD-1 monotherapy in other immunogenic ca such as melanoma. MoST-CIRCUIT is the first trial that investigated combined anti-PD-1/CTLA-4 blockade in advanced dMMR/MSI-H non-CRCs.